Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

By  

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 940-950

Bentham Science Publishers

Access to resources Recommend Favorite

3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors

By  

Medicinal Chemistry, Vol. 8, Iss. 6, 2012-11 ,pp. : 1117-1125

Bentham Science Publishers

Access to resources Recommend Favorite

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

By Varkaris Andreas   Corn Paul G   Gaur Sanchaika   Dayyani Farshid   Logothetis Christopher J   Gallick Gary E  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 12, 2011-12 ,pp. : 1677-1684

Informa Healthcare

Access to resources Recommend Favorite

MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bedside

By  

Current Medicinal Chemistry, Vol. 21, Iss. 8, 2014-01 ,pp. : 975-989

Bentham Science Publishers

Access to resources Recommend Favorite

The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 37, 2012-12 ,pp. : 6155-6168

Bentham Science Publishers

Access to resources Recommend Favorite